Paul Edwards Posted December 2, 2015 Share Posted December 2, 2015 Jill Margo edits the Australian Financial Review's Men's Health section and has won two Walkley Awards and widespread recognition for her coverage of men's health issues. Thanks to Tom for drawing our attention to these 2 articles in today's Australian Financial Review. The mystery of Macquarie Bank founder Robin Crawford's prostate cancer Radiation therapy was never suggested to him as a viable alternative. He had robotic surgery which apparently did not remove all the cancer. Despite these things, he donated $1,000,000 to help to buy a surgical robot for a cancer centre. At a personal cost of $3000 a month, Crawford is on the new drug Xtandi (enzalutamide) to keep his prostate cancer at bay. Unfortunately most of us don't have the resources to do this. Hopefully Xtandi (enzalutamide) will be approved on the PBS, sooner rather than later, for use prior to chemotherapy. Do men really have a fair choice of treatment for prostate cancer? This story is similar to the story on ABC Lateline in May this year which claimed that urologists are not giving patients the full information they need to choose their treatment. Link to comment Share on other sites More sharing options...
This topic is now archived and is closed to further replies.